Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) has appointed Garlan Adams as the new General Counsel, a role created to enhance the company’s legal strategies in rare endocrine diseases. Adams brings over two decades of experience in intellectual property and regulatory compliance. CEO Scott Struthers expressed confidence in her ability to support the development of paltusotine for acromegaly. Crinetics is advancing its pipeline, which includes therapies for various endocrine-related conditions.

Positive

• Appointment of Garlan Adams as General Counsel expected to strengthen legal and compliance framework.
• Garlan Adams brings over 20 years of relevant experience in pharmaceutical legal matters.
• Enhancement of legal support for the late-stage development of paltusotine.

Negative

• Potential concerns regarding continuity and experience gaps after a management change.

SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Garlan Adams to the newly created role of general counsel. Ms. Adams brings to Crinetics more than two decades of experience managing legal and compliance matters associated with the development and commercialization of innovative pharmaceutical and biotechnology products.

“Garlan has devoted her career to advising large and small pharmaceutical companies in the complexities of intellectual property, regulatory and compliance matters related to the development of therapeutics for the U.S. and international markets. I am confident that having Garlan’s breadth of legal experience in clinical development and commercialization will be a tremendous asset to Crinetics,” explained Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “As we evolve as a company, expand our pipeline and advance paltusotine through late-stage development for acromegaly, her counsel will be essential to our success.”

Ms. Adams was previously an advisor to Indivior, Inc. on a broad spectrum of complex compliance and litigation matters related to product commercialization including patient access, interactions with health care professionals, sales, marketing and product life cycle issues. Previously, she was general counsel at Avanir Pharmaceuticals, where she provided counsel on matters related to clinical stage development, sales, marketing, pricing and distribution, developed robust contracting processes and policies, and helped resolve compliance matters. Earlier in her career, Ms. Adams held positions of increasing responsibility at Eli Lilly & Company, Amylin Pharmaceuticals, Amgen and Onyx Pharmaceuticals, where she provided counsel on product labeling, launch readiness and on matters related to medical affairs, manufacturing, sales, marketing, pricing and compliance. She earned a Bachelor of Arts from St. Francis College in Ft. Wayne, IN and a Doctor of Law from Indiana University School of Law in Indianapolis, IN.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

FAQ

What is the significance of Garlan Adams' appointment for Crinetics Pharmaceuticals (CRNX)?

Garlan Adams' appointment as General Counsel is significant as it aims to enhance Crinetics' legal and compliance strategies, particularly in the development of its lead product candidate, paltusotine.

What experience does Garlan Adams bring to Crinetics Pharmaceuticals (CRNX)?

Garlan Adams brings over two decades of experience managing legal and compliance matters in the pharmaceutical industry, advising on intellectual property and regulatory issues.

How will Garlan Adams' role impact the development of paltusotine at Crinetics Pharmaceuticals (CRNX)?

Her expertise is expected to provide crucial legal support as Crinetics advances paltusotine through late-stage development for treating acromegaly.

When was Garlan Adams appointed as General Counsel for Crinetics Pharmaceuticals (CRNX)?

Garlan Adams was appointed as General Counsel on June 16, 2021.